SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Indications -- Psoriasis/Chronic Inflammation
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
From: Icebrg10/23/2004 4:04:43 PM
   of 631
 
Treatment of multiple sclerosis with an anti-interleukin-2 receptor monoclonal antibody.

Ann Neurol. 2004 Oct 20 [Epub ahead of print]

Rose JW, Watt HE, White AT, Carlson NG.

Neurovirology Research Laboratory, VA Salt Lake City Health Care System.

We examined whether treatment with daclizumab, a humanized monoclonal antibody specific for the interleukin-2 receptor alpha chain, was safe and efficacious in relapsing-remitting and secondary progressive multiple sclerosis patients. Nineteen ambulatory patients with clinically active disease were treated for 5 to 25 months. Seventeen patients were not responding to other immunotherapies. Daclizumab was generally well tolerated. Sustained clinical improvement (10 patients) or stabilization (9 patients) was observed. Daclizumab treatment produced significant reduction in magnetic resonance imaging activity. Ann Neurol 2004.

[This is Roche's/PDLI's mAb Zenapax, which is approved for use to prevent organ rejection during renal transplants. Who controls the rights in a potentail MS indication is not clear to me. IP has been passed between the two companies a couple of times, but my guess is that it is Protein Design. Without knowing any details I must still say that these results look very good. All patients had at least their disease stabilised and half of them witnessed what the paper claims was a "sustained clinical improvement". Whatever that may mean in this context.

Erik]
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News